# An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

> **NCT03144661** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 25 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Cholangiocarcinoma
- Esophageal Cancer
- Nasopharyngeal Cancer
- Ovarian Cancer
- Solid Tumors

## Interventions

- **DRUG:** INCB062079

## Key facts

- **NCT ID:** NCT03144661
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-25
- **Primary completion:** 2020-06-10
- **Final completion:** 2020-06-10
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Strategic Business Decision
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03144661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03144661, "An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03144661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*